Aim. To study adjuvant effect of betahistine dihydrochloride to ACE inhibitors in patients with chronic heart failure (CHF) class II-III suffering from giddiness. Material and methods . 61 patients with CHF class II-III, ejection fraction ≤45% (Simpson) suffering from giddiness were involved into randomized open parallel study. Patients were randomized to Betahistine dihydrochloride plus basic CHF therapy or only basic therapy groups. Enalapril dose titration was performed in all patients. Quality of life and giddiness severity evaluation, electrocardiogram was performed initially and after treatment. Clinical examination results, drug therapy and adverse event were registered at each visit. Results. The target ACE inhibitor dose (≥20 mg daily) was reached in 97 % of patients. It led to significant reduction of dyspnea, edemas, CHF class reduction and life quality increase. Significant differences between investigated groups were not found. Reduction of giddiness severity was shown in both groups. There was a trend to more prominent improvement of life quality (р=0,08) and more frequent achievement of target ACE inhibitor dose in patients treated with betahistine dihydrochloride. Conclusion. The target ACE inhibitor dose can be achieved more than in 90% of patients with CHF class II-III without hypotension symptoms. Adjuvant usage of betahistine dihydrochloride is necessary in patients with CHF still suffering from giddiness after achievement of target ACE inhibitor dose.

Betahistine

10.20996/1819-6446-2008-4-5-16-22

Cite

Citations (0)

Pharmacoeconomic analysis of ryzodeg®, a combination of soluble ultra-long-acting human insulin analogue (insulin degludec) and ultra-short insulin analogue (insulin aspart), use in therapy of type 2 diabetes

Pharmacoeconomics theory and practice (2015)

A.Yu. Kulikov I.V. Novikov

Insulin degludec

Insulin aspart

Insulin analog

Insulin detemir

10.30809/phe.4.2015.2

Cite

Citations (0)

Analytic Approaches to Observational Studies With Treatment Selection Bias

JAMA (2007)

I.V. Novikov Ofra Kalter‐Leibovici

10.1001/jama.297.19.2077-a

Cite

Citations (20)

Современная методология анализа чувствительности в фармакоэкономических исследованиях

Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология (2010)

Р. И. Ягудина A.Yu. Kulikov I.V. Novikov

In pharmacoeconomic modelling values of some parameters are known with high precision. Sensitivity analysis is used to estimate the impact of uncertain values on the reliability of results in modelling. In this article we go through characteristics, ways of displaying, advantages and disadvantages of different types of sensitivity analysis.

Source

Cite

Citations (0)

[The effect of small concentration of benzol on the supreme nervous function of animals under constant experiment].

PubMed (1956)

I.V. Novikov

Constant (computer programming)

Source

Cite

Citations (0)

Состояние функции внешнего дыхания у больных ревматическими пороками сердца, осложненными лёгочной гипертензией

Рациональная фармакотерапия в кардиологии (2011)

Н. А. Шостак А. А. Клименко I.V. Novikov

Source

Cite

Citations (0)